ReviewToxicologic pathology2011
Continuing education course #2: current understanding of hemostasis.
Review in Toxicologic pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 353 citations in OpenAlex.
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Akhirin Preserves Hemostatic Wound Repair Through Non-Hematopoietic Regulation of the Vascular Injury Microenvironment.Journal of developmental biology · 2026Article
- Platelet Function Disorders: Glanzmann Thrombasthenia and Type 2 Von Willebrand Disease.Cureus · 2026Article
- Platelet-to-Lymphocyte Ratio-A Real or Fake Bridge Between Inflammation and Coagulation in COVID-19 Patients: A Scoping Review.Diagnostics (Basel, Switzerland) · 2026Review
- Association Between Pelvic Injury and Trauma-Induced Coagulopathy in Severe Trauma Patients: A Retrospective Single-Center Study.Journal of clinical medicine · 2026Article
- Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Clinical pharmacology of antiplatelet drugs: implications for personalized therapy.European journal of clinical pharmacology · 2026Review
- rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation.Blood vessels, thrombosis & hemostasis · 2026Article
- Development of a multi-task learning framework with gradnorm for precise wound tissue analysis.PloS one · 2026Article
- Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?Therapeutic advances in hematology · 2026Review
- Cellular and molecular mechanisms of thrombosis and thrombus-targeted thrombolytic strategies.Materials today. Bio · 2025Review
- In Vitro Characterization of Biodegradable Polyurethane Foams With Facile Gelatin Modification for Traumatic Wound Hemostasis and Regeneration.Journal of biomedical materials research. Part A · 2025Article
- A 2D computational model of chemically- and mechanically-induced platelet plug formation.Biomechanics and modeling in mechanobiology · 2025Article
- LRRC8 complexes are ATP release channels that regulate platelet activation and arterial thrombosis.Blood · 2025Article
- Review
- Adjunctive Antithrombotic Medications to Acute Reperfusion Therapy: Current Evidence and Future Directions.Stroke · 2025Review
- Deciphering the Complex Relationships Between the Hemostasis System and Infective Endocarditis.Journal of clinical medicine · 2025Review
- Evolving FATE: A New Lens on the Pathogenesis and Management of Feline Cardiogenic Arterial Thromboembolism.Animals : an open access journal from MDPI · 2025Review
- Advanced biomaterial strategies for overcoming age-associated wound healing impairments.APL bioengineering · 2025Review
- Unveiling the role of lipid metabolism in haemorrhagic disorders: genetic insights and therapeutic perspectives.Thrombosis journal · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The goal of this review is to briefly summarize the two primary pathways of hemostasis, primary hemostasis and secondary hemostasis, as well as to summarize anticoagulant mechanisms and fibrinolysis. In addition, this review will discuss pathologies of hemostasis and the mechanisms of the various drugs that are available to impact these pathways to prevent either thrombosis or bleeding. While many of the main drugs that are used to treat disorders of hemostasis have been used for decades, greater understanding of hemostasis has led to development of various new drugs that have come onto the market recently or are close to coming onto the market. Thus, improved understanding of hemostasis continues to lead to benefits for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.